Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) EBITDA Margin (2022 - 2025)

TriSalus Life Sciences' EBITDA Margin history spans 4 years, with the latest figure at 24.77% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 6699.0% year-over-year to 24.77%; the TTM value through Dec 2025 reached 59.68%, up 6320.0%, while the annual FY2025 figure was 59.68%, 6320.0% up from the prior year.
  • EBITDA Margin reached 24.77% in Q4 2025 per TLSIW's latest filing, up from 77.94% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 24.77% in Q4 2025 to a low of 364.91% in Q4 2022.
  • Average EBITDA Margin over 4 years is 179.77%, with a median of 149.84% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: tumbled -15173bps in 2023, then soared 23957bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 364.91% in 2022, then surged by 32bps to 249.05% in 2023, then surged by 63bps to 91.76% in 2024, then soared by 73bps to 24.77% in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's EBITDA Margin are 24.77% (Q4 2025), 77.94% (Q3 2025), and 65.39% (Q2 2025).